Policy
Protagonist Therapeutics Royalty Stream Backs $300M Buyback
Protagonist Therapeutics has transitioned into a high-margin royalty compounder backed by two FDA-approved drugs, roughly $620 million in cash, and a $300 million buyback program. FDA approval of rusfertide as MIMRYLO triggered $275 million, shifting development risk to partners while retaining substantial economic upside.
pharmabiotechmanaged care
If sustains its high-margin royalty inflows and executes its $300 million buyback, watch shares of Protagonist Therapeutics (N: ) as incoming cash flows scale against estimated operational costs of $220 million.
